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Abstract 
Purpose: To test the ability of the American Association of Physicists in Medicine 
(AAPM) Task Group 119 (TG-119) commissioning process and the Imaging and 
Radiation Oncology Core (IROC) credentialing to detect errors in the commissioning 
process for a commercial treatment planning system. 
Methods: Commissioning errors were introduced into the commissioning 
process for the Anisotropic Analytical Algorithm (AAA) within the Eclipse Treatment 
Planning System (TPS).  We included errors in MLC Dosimetric Leaf Gap (DLG), MLC 
Transmission factor, electron contamination modeling parameters, incorrect flattening 
filter material, input of Tissue Maximum Ratio (TMR) rather than Percent Depth Dose 
(PDD) curves, and beam profile measurement with an inappropriately large farmer 
chamber (simulated using sliding window smoothing of the input dose profiles).  We 
evaluated the clinical impact of these errors for a variety of clinical intensity modulated 
radiation therapy (IMRT) plans by looking at dose received by 99% of the prescribed 
treatment volume (PTV D99) and mean and max dose to organs at risk (OARs). The 
different cases included a head and neck plan, low and intermediate risk prostate plans, 
a Mesothelioma plan, and a scalp plan. Finally, for the errors with substantial clinical 
impact, we determined the sensitivity of the commissioning & credentialing processes 
with the TG119 C-shape and IROC IMRT head and neck phantoms. This was 
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determined by comparing plans before and after commissioning errors were introduced 
in the commissioning process using the technique suggested by each respective 
organization. IROC IMRT credentialing includes film analysis at the midpoint between 
PTV and OAR using a 4mm distance to agreement metric along with a 7% 
thermoluminescent detector (TLD) dose comparison. The TG119 C-shape IMRT 
phantom looks at 3 separate dose planes and using gamma criteria of 3% 3mm. 
Results: The most clinically severe commissioning errors resulted from the 
importing TMR rather than PDD curves which had over 10% change in dosimetric 
indices in clinical plans. Other clinically severe changes came from large changes in the 
Multileaf Collimator Dosimetric Leaf Gap (MLC DLG) with a change of 1mm resulting 
in up to a 5% change in the primary PTV D99. This resulted in a discrepancy in the IROC 
TLDs in the PTVs and OARs of 7.1% and 13.6% respectively, which would have resulted 
in detection. While use of incorrect flattening filter caused only subtle errors (<1%) in 
clinical plans, the effect was also most pronounced for the IROC TLDs in the OARs 
(>6%). MLC Transmission Factor errors were clinically relevant with a change in 
transmission of 0.9% resulting in changes of over 7% in critical organ dose. This resulted 
in a discrepancy in the IROC PTV TLDs of 2% and 8% in the IROC OAR TLDs. IROC 
film analysis was insensitive to the commissioning errors implemented as the only error 
to fail the distance to agreement criteria for film analysis was the TMR input. TG-119 
gamma analysis was done using both relative and absolute criteria and only the absolute 
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gamma analysis was sensitive to commissioning errors, with relative gamma analysis 
not detecting even the TMR plan with a 3%, 3mm criteria. 3D dosimetric indices were 
similar in sensitivity to the IROC TLDs and were more sensitive to commissioning errors 
than the gamma analysis currently done with TG-119 commissioning. 
Conclusion: The AAA commissioning process within the Eclipse TPS is 
surprisingly robust to user error.  When errors do occur, the IROC TLD criteria and TG-
119 commissioning process are effective at detecting them; however the OAR TLDs are 
the most sensitive to errors despite the IROC currently excluding them from their 
analysis. 
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1. Introduction 
External beam radiation therapy (EBRT) is a common therapy used for treatment 
of cancer and is administered to thousands of patients every day.  Advances such as 
multi-leaf collimators (MLCs), 3D conformal radiation therapy (3DCRT), intensity 
modulated radiation therapy (IMRT), and volumetric modulated radiation therapy 
(VMAT) have increased both the effectiveness and complexity of radiation therapy. All 
of these complexities are first modeled within a computerized treatment planning 
system.  Treatment planning systems are used to perform dose calculations and develop 
a treatment plan to deliver a prescribed dose to the target volume while sparing normal 
tissue. 
With these advances it is important that proper checks and quality assurance (QA) 
procedures be in place in order to ensure that treatment is delivered properly. Quality 
assurance procedures are in place for all aspects of the commissioning and throughout 
the treatment process. These include commissioning of the TPS, commissioning of the 
linear accelerator, periodic linear accelerator quality assurance, pretreatment IMRT QA, 
and credentialing by outside institutions.  The commissioning of treatment planning 
systems and their corresponding dose calculations algorithms is a critical step in the 
treatment process. 
The commissioning process for the treatment planning system is especially 
important because any errors in this process impact all treatment plans that are created 
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using the planning system. The AAPM publication by Task Group 53 is a guideline for 
this commissioning process, and provides the framework to allow physicists to design 
comprehensive and practical treatment planning QA programs for their clinics without 
prescribing specific tests3. In addition, the report by Task Group 119 furthered this 
initiative by producing quantitative confidence limits as baseline values for 
commissioning IMRT planning and delivery systems4.   TG-119 provides various 
phantom geometries for which an institution can test IMRT in their treatment planning 
system by creating treatment plans, optimizing, delivering, and verify using dose 
measurements. TG-119 also reported agreement between calculated dose and film 
planes for multiple institutions, which can serve as a reference of achievable agreement. 
Another means to verify the TPS and IMRT commissioning process is through 
credentialing processes offered by outside institutions. The most common inter-
institutional credentialing is through the Imaging and Radiation Oncology Core (IROC, 
formerly the RPC). The Radiation Therapy Oncology Group (RTOG) requires 
credentialing with the IROC prior to participation in their clinical trials involving IMRT 
delivery. IROC credentialing process is designed to detect any errors that may have 
occurred during the commissioning of a treatment planning system. The process 
consists of the IROC sending a phantom with 8 thermoluminescent detectors (TLDs) and 
film inserted. The institution then simulates and creates an IMRT plan based on the dose 
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constraints given by the IROC. The institution irradiates the phantom and returns the 
phantom with the dose measurements and calculated dose for the TLDs and film planes. 
Currently there is little data regarding the sensitivity to commissioning errors of 
IMRT commissioning using the TG-119 guidelines and credentialing via the IROC. 
However; a number of studies have been done to evaluate the clinical effect of 
commissioning errors. Work has been done showing that gamma analysis and planar 
dose comparisons are insufficient in detecting clinically relevant dose errors18 and that 
Dose Volume Histogram based QA metrics are more effective than gamma pass rates in 
pretreatment dose QA17. Tolerances have been determined for beam modeling based on 
equivalent uniform dose (EUD) in clinical plans using multiple beam models in the 
Pinnacle TPS8. Biological consequences of MLC calibration errors have been evaluated. It 
has also been found that for low modulation plans there is a better chance to catch MLC 
calibrations errors with 3D gamma measurements rather than ion chamber 
measurements, whereas for highly modulated plans there is a better chance of catching 
MLC calibration errors with ion chamber QA rather than with 3D gamma QA9. 
Further studies evaluated the dosimetric impact of MLC leaf position 
errors on clinical treatment plans and found that systematic MLC errors had 
considerable impact10.  In a separate study they evaluated the feasibility of 
detecting systematic MLC leaf bank errors using a 2D diode array and an on 
board EPID and found that an absolute dose comparison using a gamma analysis 
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(3%, 3mm) could detect a 0.5mm error, while a relative comparison of the planar 
dose was insensitive to errors11. To analyze the effect of MLC commissioning 
errors on clinical volumetric modulated arc therapy (VMAT) plans, methods 
have been developed and it was found that the clinical effect was dependent on 
optimization results from the TPS.  A correlation was shown between dose error 
and average leaf gap width12. A number of studies have evaluated the sensitivity 
of 1D & 2D detectors to commissioning & delivery errors.  For example it was 
found that radiochromic film and a diode matrix could only detect systematic 
MLC errors on the order of 2 mm or above13.  
Both TG-119 commissioning and IROC credentialing use 2D planar 
dosimetry measurements to evaluate the accuracy of treatment planning 
systems. Film has high spatial resolution but only samples select planes of the 
treatment volume, limiting the capability to detect inaccuracies elsewhere within 
the treatment volume and organs at risk. 3D dosimetry techniques have been 
developed that can sample the entire 3D dose distribution. Examples of 3D 
dosimeters include gel and polymer based dosimeters14. 3D dosimetry can 
achieve high spatial resolution and has been applied to a range of radiotherapy 
energies, modalities, and applications, including verification of IMRT14, 15, 16. After 
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irradiation, the measured 3D dose matrix can be read out from these 3D 
dosimeters using MRI (in the case of gel dosimeters) or optical tomography15.  
3D dosimetry is well suited for IMRT commissioning with TG-119 and IROC 
credentialing for a number of reasons: (1) the additional effort required to perform 3D 
dosimetry over other less comprehensive measurements may be warranted due to the 
critical need for correct commissioning of the TPS and the potential severity of errors 
committed during this process. (2) Both the TPS commissioning and credentialing 
processes are carried out on an infrequent rather than on a recurring basis; hence the 
additional effort for 3D dosimetry would not affect the clinic workload of recurring 
quality assurance. (3) In the case of IROC credentialing, the phantom, film planes, and 
TLDs are already transferred to a central location; hence the 3D dosimetry technology 
would not need to be disseminated on a widespread scale.  However the question 
remains as to how much benefit 3D dosimetry techniques would provide over current 
1D & 2D measurements.  
The purpose of this project was to test the ability of the TG-119 guidelines for 
IMRT commissioning and IROC credentialing to detect errors in the commissioning 
process of IMRT within a commercial Treatment Planning System (TPS). We also 
evaluated if using 3D dosimetric indices would increase the sensitivity of IROC 
credentialing and TG-119 commissioning procedures in detecting commissioning errors. 
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2. Materials and Methods 
2.1. Overview 
Figure 1 is an overview of the methods used for this study. To measure each QA 
technique’s sensitivity and ability to detect errors, first the errors were implemented in 
the Eclipse Analytic Anisotropic Algorithm during the commissioning process. One 
error was implemented at a time to isolate the effect of each individual mistake made 
during the commissioning process. Once the algorithm was commissioned with an 
intentional error, the dose for clinical plans was recalculated using the altered algorithm 
and compared to the original plan to measure the impact that the commissioning error 
would have clinically. To measure the sensitivity of the IMRT commissioning process 
and IROC credentialing, the same was done with plans designed on the TG 119 C-Shape 
and IROC Head and Neck IMRT phantoms. The newly calculated plans were then 
compared to the original plans and evaluated using their respective criteria to determine 
the dosimetric effect of each error.  
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Figure 1: A schematic of the general procedure. 
 
2.2. Treatment Planning System 
2.2.1 Beam Data Input 
The beam data requirements include collections of machine specific and 
geometry specific parameters along with measured beam data. This measured data must 
all be taken at the same beam geometry and under the same setup conditions for the 
algorithm to be able to apply it. The measured beam data consists of depth dose curves 
and profiles using the same field sizes performed on the same axis and with a consistent 
source-surface distance of between 70 and 140 cm1. The beam data used in our 
configuration was taken at a source-surface distance of 100 cm. 
  
intentional error 
linac geometry  
& beam data 
original dose  
calculation algorithm 
altered dose  
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clinical treatment  
plans 
IROC Phantom 
treatment plan 
TG-119 phantom 
treatment plan 
clinical severity of  
commissioning error 
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to commissioning error 
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Table 1: Breakdown of Treatment Planning System commissioning parameters. 
Primary  Output Factors 
Depth Dose Curves 
Beam Profiles 
Spectrum Parameters 
Secondary Mean Radial Energy 
Size of Second Source 
Relative Intensity 
Mean Energy of Second Source 
Electron Contamination Electron Contamination σ0 
Electron Contamination σ1 
Relative Fraction 
MLC Parameters Dosimetric Leaf Gap 
Transmission Factor 
 
Table 1 shows each of the elements that go into the commission procedure and 
where they fall in terms of dose contribution. Primary parameters are those used to 
model the primary source of photons, which consists of bremstrahlung X-rays produced 
in the target that do not interact in the head of the treatment unit. Secondary parameters 
are those used in modeling the dose from photons scattered from the flattening filter and 
collimators, and is modeled as a virtual plane source located at the bottom of the 
flattening filter. Electron contamination parameters model the dose contribution from 
electrons generated in the treatment unit head and in air (mainly through Compton 
scattering).    The electron contamination is modeled at the target plane using two 
Gaussian curves (which determine lateral spread of electrons & field size dependance) 
and one dose deposition curve which is derived empirically by the beam modeling 
algorithm as the difference between the largest field size depth dose curves measured 
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with and calculated without the electron contamination.  Finally, the MLC parameters 
model the complex interactions with the field incident upon the collimator leaves. 
Electron contamination and MLC parameters are described in more detail in the 
following sections. 
The required measured beam data also includes depth dose curves along the 
central axis in water taken for field sizes of 4x4  cm2, 6x6  cm2, 10x10 cm2, 20x20 cm2, and 
for the largest possible field size which for this machine was 40x40 cm2. Additionally 
recommended and used in our configuration were depth dose curves for the smallest 
possible field size which was 2x2 cm2, along with curves for 8x8 cm2 and 30x30 cm2. 
Dose profiles are required from all field sizes at depths of dmax (1.5 cm for 6 MV 
photons), 5 cm, 10 cm, 20 cm, and 30 cm depths. Dose profiles are taken using both 
inline and crossline scans and for large field sizes diagonal scans are used. For the 
diagonal scans the tank is offset and only half of the profile is measured. The diagonal 
scans are then mirrored to create a full dose profile.  
The final piece of measured beam data is the output factors. Output factors are 
typically measured at a depth of 5 cm and are displayed as a ratio of measured dose at 
depth for each measured field size with respect to the dose at the reference field size of 
10x10 cm2. Output factors are required for each of the rectangular field sizes displayed in 
Table 1.  A new table of output factors is then interpolated by the TPS at 1 cm resolution.  
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Table 2: Field sizes required for Open Field Output factors1. 
 
The required general machine parameters include source-axis distance (SAD) as 
well as the smallest and largest allowable open beam field size in each direction. This is 
also where information about the profiles is input so that the TPS knows information 
about the depth at which the profile is taken. The general parameters table is shown in 
Figure 2. Beyond the general parameters is a second set of parameters that define the 
absolute dose calibration of the machine.  These parameters include machine type, 
calibration depth and absolute dose at calibration depth. 
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Figure 2: General Beam Parameters as input into Eclipse. 
 
2.2.2 Calculation of Beam Model 
Using this input information and an existing library of machine data, further 
information is extracted from the machine library and calculated within the AAA beam 
modeling algorithm  such as Mean Radial Energy, Intensity Profiles, Electron 
Contamination parameters, and spectrum parameters. The mean radial energy and 
initial photon energy spectrum in the machine parameter library is pre-determined from 
Monte Carlo simulations of the bremsstrahlung spectrum of electrons incident on the 
target. Electron contamination is modeled using a 2D Gaussian second source1. From 
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this second source modeling the electron contamination curve is calculated and 
convolved into dose distribution. Other parameters calculated by the treatment planning 
algorithm are the Mean Radial Energy Curve, Intensity Profile Curve, and Energy 
Spectrum. Mean Radial Energy and Intensity Profile are functions of distance off axis, 
and the Energy Spectrum shows the fluence per energy. 
2.2.3 Verification 
After the AAA beam modeling algorithm is prepared, the TPS allows the user to 
evaluate the agreement between the calculated and the measured curves. This 
comparison is done for all input beam profiles, diagonal profiles, and depth dose curves.  
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Figure 3: Comparison of Original Calculated Beam Profile with no error and 
Measured Beam Profiles done in Verification. 
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2.2.4 Dosimetric Leaf Gap and MLC Transmission Factor 
The Dosimetric Leaf Gap and MLC Transmission Factor are not included in the 
dose calculation algorithm commissioning process. Values are input through the Beam 
Configuration window in Eclipse in the beam data tab under dosimetric data, which is 
done as a part of IMRT commissioning after the AAA beam modeling algorithm has 
been completed.  
 
 
2.3 Implementation of Errors 
We introduced the following types of commissioning errors into the 
commissioning of the AAA beam modeling algorithm: alterations to MLC dosimetric 
leaf gap (MLC DLG), MLC transmission factor, flattening filter material, and electron 
contamination modeling parameters, input of Tissue-Maximum Ratio (TMR) as opposed 
to Percent Depth Dose (PDD) curves, and smoothing the input dose profiles to simulate 
measuring the beam data using an inappropriately large farmer chamber. When changes 
were made in the flattening filter material, the system would automatically modify 
second source parameters such as the size or mean energy of the second source. These 
automatic modifications are made to ensure that the calculated and measured dose 
curves match well, thus minimizing the clinical impact it would have if a mistake were 
made in entering the flattening filter material. While the system automatically 
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compensates for some errors by modifying other beam parameters, the AAA beam 
modeling system does not compensate for differences in MLC DLG. 
The first type of error that was introduced was alterations in the Dosimetric Leaf 
Gap. The MLC DLG is a parameter used to model the complex interactions with a beam 
incident upon the leaves of a MLC such as lateral disequilibrium6, tongue-and-groove 
effect, and rounded leaf-end effect. To account for these effects the dose calculation 
algorithm assumes a gap between the ends of leaf pairs.  The magnitude of this gap is 
set by the physicist and can be determined by comparison of line profiles of delivered 
and calculated dose7. In our case, the original DLG was set to 1.8mm.  We then 
implemented errors ranging from 0.1 to 1 mm from the nominal value.  
Next, changes were made to the MLC Transmission Factor. The transmission 
factor models leakage dose through the MLC leaves. The transmission factor is 
determined using film measurements and determining the percentage of dose that is 
delivered to the blocked areas19. The original value of the MLC Transmission Factors as 
set in IMRT commissioning of this machine is 0.017, representing that 1.7% of the dose 
delivered is transmitted to areas blocked by the MLC leaves. We implemented changes 
in transmission factor of magnitude of 0.5% and 0.9% by changing this value to .022 and 
.026, respectively. 
 The next phase of commissioning errors implemented was the material of the 
flattening filter. The flattening filter is used in linear accelerators to preferentially 
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attenuate the beam at the center resulting in a beam hardening effect with the ultimate 
goal of achieving a flat dose profile at treatment depth. The AAA beam modeling 
algorithm allows the user to select the flattening filter material; we changed the material 
of the flattening filter from Copper to any of the other materials listed as possible 
flattening filters, which includes Tungsten, Lead and Iron. During the first step of the 
commissioning process machine parameters are input and using these parameters the 
TPS accesses a machine library that includes information about the specific machine that 
is being commissioned. To change the flattening filter from Copper to a different 
material, one must skip the step of the commissioning process that retrieves parameters 
from the machine library. Upon selecting an incorrect flattening filter material, the beam 
spectrum is altered.  The AAA beam modeling algorithim then compensates for this by 
changing the second source parameters, resulting in close agreement between calculated 
and measured dose profiles and depth dose curves. 
Another set of parameters retrieved from the machine library are the electron 
contamination parameters. Electron contamination fluence is simulated within the dose 
calculation algorithm using a convolution of aperture shape and a 2D sum-of-Gaussians 
kernel1. The parameters available for electron contamination are two different sigma 
values that model the lateral distribution for each Gaussian curve and a relative fraction 
specifying the weight of each Gaussian. The initial values from the machine library for 
σ0 is 69.99 mm, σ1 is 99.99 mm, and a relative fraction of 0.4384. The default 
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commissioning procedure will set these values automatically. To alter these values, the 
user must skip a step of the configuration process so that the values are not reset. For 
this project, changes were made in σ0 of magnitude of 70 mm. 
The next error implemented was to input TMR curves rather than PDD curves. 
Tissue Maximum Ratio, unlike Percent Depth Dose does not account for inverse square 
falloff and is simply a ratio of the dose at a given depth relative to the maximum dose 
given the same SAD for both measurements. Percent Depth Dose is also a ratio of dose 
but accounts for the change in distance from the source with depth. For input into the 
TPS, PDDs should be measured for the linear accelerator in water. To convert from PDD 
to TMR, a function in the beam data collection software was used for each field size and 
values at certain depths were verified by hand. Once TMR curves were input into the 
system instead of PDD curves, the commissioning process was carried out in its entirety. 
The final error implemented was a smoothing of dose profiles to simulate the use 
of an inappropriately large farmer chamber while collecting the profiles. To do so, 
profiles were smoothed using an arithmetic mean smoothing method with a sliding 
window size of 6 mm in the beam data collection software. This sliding window size 
was used to simulate a large diameter chamber used to collect the data. These overly 
smoothed profiles were input to the TPS in place of the proper dose profiles and 
commissioning was carried out in its entirety. Figure 4 shows the smoothed profiles in 
blue and orange and the original, unsmoothed profiles in red and green. 
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Figure 4: Comparison of 6mm smoothed profiles to unsmoothed profiles for 2x2 cm 
and 10x10 cm field sizes. 
2.4 Clinical Impact 
To determine the clinical impact that these commissioning errors had, they were 
analyzed using standard dose metrics for five clinical plans. The plans used included a 
low risk prostate plan, an intermediate risk prostate plan, a head and neck plan, a 
Mesothelioma case, and a scalp case. Each of these plans has different source to surface 
distances (SSD), target volume sizes, and organs at risk near the treatment volume but 
all plans used a 6X beam for treatment. The variety allows us to examine how different 
errors would impact different clinical plans depending on these differences. The head 
and neck case and the scalp plan were the only plans used to analyze changes in electron 
contamination metrics as they were the only cases with critical structures within the 
electron range distance from the surface.  To analyze the clinical impact of these errors, 
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we looked at d99 and d1 of the PTVs as well as mean or max dose statistics of nearby 
critical organs depending on if those organs were serial or parallel. The Mesothelioma 
case was used primarily to determine the effects of these errors in low dose regions. To 
quantify this, we considered the volume of the non treated lung to receive dose over 5 
Gy, 13 Gy, and 30 Gy as well as the volume of the heart to receive over 38 Gy or 42 Gy. 
The prostate plans required the deepest penetration of any of the plans considered and 
were used in determining the impact of the implemented errors at depth. The original 
treatment plans are illustrated in Figures 5-9 as well as the Dose Volume Histograms 
showing the original dosimetric indices for each plan. 
 
Figure 5: 3D rendering, Axial, and Sagittal Dose Distribution and DVH of Head and 
Neck Plan. 
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Figure 6: 3D rendering, Axial, and Sagittal Dose Distribution and DVH of 
Intermediate Risk Prostate Plan.
 
Figure 7: 3D rendering, Axial, and Sagittal Dose Distribution and DVH of Low Risk 
Prostate Plan. 
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Figure 8: 3D rendering, Axial, and Coronal Dose Distribution and DVH of 
Mesothelioma Plan. 
 
Figure 9: 3D rendering, Axial, and Sagittal Dose Distribution and DVH of Scalp Plan. 
 22 
2.5 Sensitivity to Errors of IMRT Commissioning TG-119 
Phantom 
The sensitivity of the TG-119 IMRT commissioning process was evaluated by 
recalculating the dose distribution of a previously optimized plan using the altered 
AAA beam model. TG-119 gives two cases for C-shape phantoms, one that is easier to 
optimize with the central core structure receiving 50% of the prescribed dose, and a 
more difficult to optimize plan with the central core structure receiving only 20% of the 
prescribed dose. For this project the easier to optimize plan was used because we would 
expect this plan to be less sensitive to errors. The TG-119 C-shape phantom is assessed 
using three planar film measurements and evaluated using a two dimensional gamma 
analysis with the criteria of 3% dose 3mm distance to agreement. The three planes are 
shown in figure 10. When discussing the gamma analysis, the transverse plane shown in 
the top right will be referred to as the z plane, the coronal plane shown in the bottom left 
will be referred to as the y plane, and the sagittal plane shown in the bottom right will 
be referred to as the x plane. 
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Figure 10: 3D rendering and planar views of the TG-119 C-shape IMRT phantom.  
 
2.6 Sensitivity to Errors of IROC Credentialing 
During the IROC credentialing process, the IROC analyzes the institution using 
point doses measured by eight TLDs within the IMRT head and neck phantom, four in 
the primary PTV, two in a secondary PTV, and two in the OAR, one superior and one 
inferior. To pass the IROC credentialing, the point dose measurements within the PTVs 
must be within 7% of the expected value.  While all TLDs are measured, only the TLDs 
within the PTVs are considered during the IROC analysis. A sagittal film measurement 
is also measured and evaluated by the IROC using a 4mm distance to agreement metric 
for the midpoint dose between the PTV and OAR. The ability of IROC credentialing 
process to detect commissioning errors was tested by recalculating the dose distribution 
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of the plan administered to the respective phantoms using AAA after the changes had 
been made. Using the same criteria, we determined the discrepancy of errors introduced 
during commissioning. 
 
Figure 11: IROC IMRT Head and Neck phantom. The Primary PTV is PT66, 
Secondary PTV in PTV54 and the Organ at Risk is the cord. The Sagittal film plane 
can be seen through the center of PTV66 and the cord. 
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2.7 Potential Benefit of 3D dosimetry for TG-119 and IROC 
The TG-119 commissioning process and the IROC credentialing processes use 
two dimensional film analysis and TLD measurements to evaluate the agreement 
between the IMRT calculation and delivery. In an attempt to evaluate the possible 
benefits of using 3D dosimetry in TG-119 commissioning and IROC credentialing, we 
calculated dose volumes for each plan with and without introducing commissioning 
errors. We then evaluated the change in relevant dosimetric indices based on the 
contoured organs at risk taken from the dose volume constraints of the plan.  We 
determined the sensitivity of these indices from the 3D dose distributions to 
commissioning errors and compared it to the sensitivity of the current 2D practices used 
in TG-119 and IROC credentialing. 
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3 Results 
3.1 Overview 
Table 3 summarizes the clinical severity of the various commissioning errors and 
probability of the errors being detected by the treatment planning system during dose 
calculation algorithm preparation stage. It also includes the probability of their being 
detected during commissioning following the TG 119 guidelines and during 
credentialing through the IROC. Clinical severity and detection probability were graded 
as low, medium, or high based upon our results. For clinical severity and TLD detection 
Low was given if the effect was less than 2%, Mid if the effect was between 2% and 7%, 
and High if the effect was greater than 7% which would fail the IROC credentialing 
criteria for the TLD measurements. The ability of the TPS to detect errors was graded as 
High when the system gave a visual warning and did not allow the user to continue, 
was graded as Mid if the error could be detected visually during the verification stage 
but no warning was given, and Low if there was no indication from the TPS that an 
error occurred. The clinical severity of Electron Contamination errors was ranked as 
Low-Mid because it only had a non-negligible (2.1%) effect on one of the five clinical 
plans analyzed (the scalp plan). A Low-Mid ranking was also assigned to the ability of 
TPS to detect flattening filter material errors as a step of the commissioning process in 
which parameters are retrieved from the machine library must be skipped for the error 
to be implemented.  
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Table 3: Summary of clinical severity and probability of detection for errors 
implemented in Eclipse AAA. 
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3.2 Clinical Impact 
3.2.1 Dosimetric Leaf Gap 
Because MLC DLG is input apart from the AAA beam modeling algorithm, 
errors in the DLG were the least likely to be detected by the TPS. The input of an 
incorrect DLG was straightforward and the effects of input of an improper DLG value 
was undetectable looking at the comparison between calculated and measured dose 
profiles during verification. As shown in Figures 12, 13, and 14, the relationship between 
the magnitude of change in the DLG value is proportional to the dosimetric effect 
induced by the error. Interestingly, the slope of correspondence between the magnitude 
of error and dosimetric effect varies between organs. The most sensitive organs to 
changes in the DLG are the parotid glands, in which a 2% dosimetric effect occurs with a 
change in DLG of 0.2 mm and a 5% dosimetric effect with a change of 0.5 mm. Prostate 
plans however were less sensitive to changes made in DLG values with all dosimetric 
indices remaining within 2% for 0.5 mm changes.  This is true for the PTVs of all plans, 
with the only dosimetric indices outside of 2% being the lens and optic nerve in the scalp 
case. 
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Figure 12: Display of change in dose from original Head and Neck plan with changes 
in the MLC DLG. 
 
Figure 13: Display of change in dose from the original LR prostate plan with changes 
in the MLC DLG. 
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Figure 14: Display of change in dose from original IR prostate plan with changes in 
the MLC DLG. 
3.2.2 MLC Transmission Factor 
Making changes to the MLC transmission factor value was also done apart from 
the AAA beam modeling algorithm and was undetectable in the verification stage of the 
TPS commissioning process. Similarly to DLG errors, the magnitude of changes in 
transmission factor was proportional to the dosimetric effect induced by the error.  The 
most sensitive plans to transmission factor errors were the head and neck plan and scalp 
plan. In the head and neck plan a 0.9% change in transmission factor resulted in a 7% 
change to the mean dose to the right parotid and a 0.5% change in transmission factor 
resulted in a 4% change to the mean dose to the right parotid. In the scalp plan a 0.9% 
change in transmission factor resulted in an 8% difference in the maximum dose to the 
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right optic nerve and a 0.5% change in transmission factor resulted in a 5% change in the 
maximum dose to the right optic nerve. The prostate and lung plans were less sensitive, 
with these same changes in transmission factor resulting in changes of less than 2% in 
relevant dosimetric indices. 
3.2.3 Flattening Filter Material 
The TPS was more sensitive to detecting changes made in flattening filter 
material in that it would reset the flattening filter material to the proper value when 
retrieving parameters from the machine library. If the user manually overrode the 
retrieval from the machine parameter library, the AAA beam modeling algorithm still 
compensated for the incorrect flattening filter setting by changing other parameters, 
specifically size, relative intensity and mean energy of the second source.  As a result, 
the beam model matched the input profiles with the exception of the penumbra region 
where 5% differences occurred. The clinical impact of changing the flattening filter in the 
TPS was minor in all of the plans considered, resulting in a mean change of within 0.3% 
in all of the clinical plans and a maximum change of 2.3% in the parotids in the head and 
neck plan which is a very low dose region that receives less than 9% of the prescription 
dose.  
3.2.4 Inappropriately large farmer chamber 
Implementation of an inappropriately smoothed dose profiles went relatively 
undetected by the TPS. Similarly to the incorrect flattening filter material, differences 
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could be detected within the TPS during the verification process by looking at the 
penumbra of the dose profiles where there was up to a 10% difference in the penumbra 
region. In general the clinical effect was minimal and within fractions of a percent, with 
the exception of the V20 in the untreated left lung in the Mesothelioma case which saw a 
change of more than 6% its original value. The effect of smoothing was minimized 
within the TPS because the calculated profiles matched the actual profiles better than 
they matched the input (smoothed) profiles.  While the AAA beam modeling algorithm 
attempts to match the calculation with the measured profiles, the differences detected 
between the two near the penumbra show that the TPS partially corrected the user error 
and decreased the effect that using an inappropriately large farmer chamber would have 
on the dose calculation algorithm. 
3.2.5 TMR 
Clinically, input of TMR instead of PDD was the most severe of the errors made 
during the commissioning process. TMR errors had large clinical impact, with a mean 
difference in dosimetric indices of over 13% in prostate plans. All plans had changes in 
some dosimetric indices of over 5% with the least sensitive plan being the scalp case. 
This is unsurprising as the scalp case consists mainly of dosimetric indices near the 
surface and the largest discrepancies between TMR and PDD occurs at deeper depths. 
Figure 15 shows a comparison of planar dose distributions for the original and TMR 
calculated intermediate risk prostate plan. 
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Figure 15: Comparison of isodose distributions for the original Intermediate Risk 
Prostate plan (right) compared to TMR (left). 
3.2.6 Electron Contamination 
Electron contamination was the most difficult error to implement into the 
system. The TPS normally retrieves the electron contamination parameters from the 
machine library, so to make any alterations to the parameters requires that the user 
prevent the TPS from searching in the machine library. After the user skips this step and 
makes a change to the parameters, the user must skip the second step of the 
configuration process to prevent the value from being changed back to their original 
values.  It therefore requires that multiple errors be made by the user, or alternatively 
that the values retrieved from the library be corrupted.  Upon calculation of the percent 
depth dose curves and dose profiles, the user can then see a notable difference of up to 
20% in the surface dose in the PDD for changes of 70 mm in σ0. The only plan that saw 
any considerable dosimetric effect was the scalp case with a maximum dose difference 
of over 2% in the mean dose to the right lens. Hence the AAA beam modeling algorithm 
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within the Eclipse TPS is very robust and resistant to electron contamination errors as 
they require multiple errors and input of values very far from the original values, and 
there is only a clinical effect of such errors for a PTV or OARs neat the skin surface. 
3.2.7 SSD changes 
Changes to the source to surface distance are expected to have a very large 
dosimetric effect if they were to be implemented. However; the system prohibited the 
user to enter an incorrect SSD giving the error “Internal Error occurred in analyzing 
basic beam measurement data”. The user was prevented by the TPS from proceeding 
without correcting the error. 
3.3 TG-119 
TG119 C-shape phantom was relatively ineffective at detecting errors using 
analysis of dose statistics and distance to agreement test of planar films. For the DLG 
changes, the gamma pass rates varied as one would expect, with high pass rates for the 
small changes that had small dosimetric effects and lower pass rates for the larger 
changes that had more severe dosimetric effects. Figure shows the current effectiveness 
of TG-119 film analysis at detecting errors along with the potential for improved 
sensitivity by changing the gamma analysis metric from 3% 3mm to 2% 2mm. The 
vertical lines in Figure represent the DLG error from which we could see a clinical 
difference of 2% and 5% respectively. Using the current 3% 3mm gamma criteria, these 
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errors are within the standard deviation of pass rates among treatment centers that 
submitted their results4. 
 
Figure 16: Effectiveness of TG-119 at detecting Dosimetric Leaf Gap errors and TMR 
input. 
   
For changes in flattening filter material as well as over smoothing of dose 
profiles, TG-119 did not detect any errors and all of the different materials had pass rates 
of 100% in all planes. Since the dosimetric effect of these errors was minimal it is not 
surprising that TG-119 would have difficulty detecting any difference. Large changes in 
electron contamination parameters went undetected by TG-119 film analysis as all three 
planes had pass rates of 100%.  
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Table 4: Pass Rates for various gamma criteria for each error in TG-119 film planes. 
Type of Error 3% 3mm Absolute 
gamma analysis 
2% 2mm Absolute 
gamma analysis 
3% 3mm Relative 
gamma analysis 
MLC DLG  
.5 mm 
98.03  ±  1.96 %  96.17 ± 1.96 % 100 ± 0 % 
MLC DLG  
1 mm 
77.43 ± 7.97 % 68.4 ± 6.84 % 93.07 ± 8.22 % 
Transmission Factor 
0.5% change 
95.89 ± 3.55 % 95.05 ± 4.05 % 97.33 ± 2.29 % 
Transmission Factor 
0.9% change 
92.02 ± 5.16% 88.72 ± 6.49 % 95.15 ± 3.92 % 
Incorrect FF 
material 
100 ± 0 % 100 ± 0 % 100 ± 0 % 
Smoothed for 
farmer chamber 
100 ± 0 % 100 ± 0 % 100 ± 0 % 
TMR vs. PDD 53.37 ± 6.10 % 44.97 ± 4.19 % 98.13 ± 2.34 % 
Electron 
Contamination 
100 ± 0 % 100 ± 0 % 100 ± 0 % 
 
The most easily detected error was the input of TMR instead of PDD, which was 
expected as it had the largest dosimetric effect in the clinical plans with pass rates below 
50% for an absolute gamma analysis with criteria of 3% 3mm. However, when analyzed 
using a relative gamma comparison in which both the original and the TMR planes were 
normalized to their maximum values the pass rates were better than 95% for all planes. 
The same was true for DLG errors analyzed with relative gamma analysis for which a 
0.5 mm change in DLG went completely undetected with a 100% pass rate.  This 
emphasizes the need for an absolute rather than relative dose comparison, as a relative 
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comparison can miss even drastic commissioning errors, as shown both in table 5 and 
figure 17.
 
Figure 17: Original Axial Dose Plane (Left) and Relative Gamma Map (right) for TMR 
comparison with the TG-119 C-shape phantom. This relative gamma analysis was 
done with a criteria of 3%, 3mm and had a pass rate of 95%. 
 
3.4 IROC 
Figures 18 and 19 show the sensitivity of IROC TLDs to various commissioning 
errors. While the PTV TLDs were effective in detecting clinically relevant errors such as 
the DLG errors as shown in Figure 18, Figure 19 shows that the OAR TLDs are much 
more efficient in detecting errors in flattening filter material and MLC transmission 
factor.  
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Figure 18: Sensitivity of point dose measurement to flattening filter, smoothing 
changes, and transmission factor changes in IROC IMRT phantom. 
 
Figure 19: Sensitivity of point does measurement to dosimetric leaf gap changes in 
IROC IMRT phantom. 
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IROC TLD measurements were effective in detecting TMR errors as there was a 
mean difference of 10% between the original plan and the TMR plan. 
The sagittal film planes were analyzed and the only error that did not meet the 4 
mm distance to agreement criteria was the TMR error which had a distance to 
agreement of 6mm. All DLG errors, flattening filter errors, and profile smoothing each 
fell well within the 4 mm criteria with no distance to agreement greater than 1mm. 
 
Figure 20 : Sample of IROC film comparison analyzed with distance to agreement 
metric of 4mm. 
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3.5 3D Dosimetry 
3D dosimetry analysis of the TG-119 C-shape phantom proved to be very 
sensitive to DLG errors, specifically with OAR indices changing more than 6% for a 0.5 
mm change and more than 14% for changes of 1 mm as shown in Figure 21. Figure 23 
shows the sensitivity of 3D dosimetric indices in the TG-119 C-shape phantom to 
flattening filter and smoothing errors, which while they did show a difference were so 
small in magnitude that they would not be detectable.  
3D dosimetric analysis as applied to the IROC IMRT head and neck phantom 
was also sensitive to DLG errors with the cord as the most sensitive dosimetric index to 
errors. The max dose to the cord changed by over 6% for a 0.5 mm shift and over 13% for 
a 1 mm difference as shown in Figure 24.  
 3D dosimetry proved to have advantages over the 2D techniques currently used 
in TG-119 commissioning. Absolute 2D gamma analysis as recommended by TG-119 is 
relatively insensitive to DLG errors with 0.5 mm shifts still within the standard 
deviation of treatment centers that submitted data. Relative gamma analysis was 
minimally sensitive to all errors, with TMR errors passing at a 99% rate and 0.8 mm DLG 
shifts passing at a 100% rate. 3D dosimetric analysis was very sensitive to TMR errors, 
with over a 10% difference in all 3D dosimetric indices considered. The difference in 
sensitivity between 3D dosimetric analysis and relative gamma analysis is shown 
between Figures 17 and 22.  
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Figure 21: Sensitivity of 3D dosimetric indices to DLG errors. 
 
Figure 22: DVH comparison for TG-119 C-shape plan between the original plan 
(triangles) and TMR plan (squares). The core OAR is shown in blue and the PTV is in 
red. 
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large detector being used during the collection of beam data. While these differences 
were detected more with 3D indices than gamma analysis, the effects of the errors were 
negligible. 
 
Figure 23: Sensitivity of 3D dosimetric indices in TG-119. 
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considered and each detection method used by measuring the slope of plots of percent 
change in dosimetric indices versus change in DLG value.  
 
Figure 24: Sensitivity of 3D dosimetric indices in IROC phantom. 
 
Figure 25 : Sensitivity of clinical cases and detection methods for DLG errors. 
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4 Discussion 
In our observation, the AAA was robust at preventing errors from being 
implemented. Many errors were prohibited by the TPS because it was able to detect that 
the input parameters were incorrect (in the case of second source parameters), or 
geometrically impossible (in the case of SSD changes). Beyond not allowing certain 
changes, the AAA commissioning process was able to correct user error by altering 
other parameters in many cases and fitting the calculated beam modeling data to fit the 
measured beam data. For example, in implementing incorrect flattening filter material, 
the machine recalculated parameters including the size of second source, mean energy 
of second source, and relative energy of the second source to compensate for the 
incorrect energy spectrum resulting from the wrong flattening filter material. These 
alteration made by the machine shaped the calculated dose profiles and depth dose 
curves to more accurately match the measured dose profiles and depth dose curves 
input by the user that had the copper flattening filter.  By altering these second source 
parameters, the spectrum was corrected so that the calculated and measured curves 
matched within 5% at all points throughout the curves. In the case of the overly 
smoothed dose profiles the calculated profiles matched the actual beam profile better 
than the smoothed profile along the penumbra.   
 
 45 
In the IROC credentialing, TLD point does measurements along the critical 
structure meant to be avoided are measured but not analyzed. In our data these TLDs 
were the most sensitive to detecting certain commissioning errors. Our results indicate 
that these measurements may be useful to include in credentialing as they were the most 
sensitive overall to errors. However, the OAR TLDs were overly sensitive to errors that 
clinically had minor effects. 3D dosimetric indices were generally better correlated to the 
clinical severity of the errors implemented. In order to detect the errors in electron 
contamination parameters or MLC transmission factor, dose measurements would need 
to be made in low dose regions and, in the case of electron contamination, near the 
surface.  
Recently, an effort has been made to failure mode and effects analysis (FMEA) to 
the field of radiation therapy as a means of reviewing the many components of the 
treatment process that could go wrong2. FMEA is a primarily qualitative analysis of a 
complex system that is a systematic technique for failure analysis. It involves three steps: 
(1) the probability that a specific cause will results in a failure mode. (2) The severity of 
the effects of a failure mode should it go undetected. And (3) the probability that the 
failure mode resulting from the specific cause would go undetected.  It is able to account 
for each possible cause of failure in a system and if applied to IMRT could serve as an 
effective means of identifying the cause of failures or errors depending on their 
probability of occurrence and probability of detection at each step of the process2. Our 
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results have implications for this process, specifically table 2 and may be useful when 
assessing severity and probability of various commissioning errors. In table 2, the 
‘Ability for TPS to detect’ column addresses the probability of an error occurring. The 
‘Clinical Severity’ column addresses the clinical relevance of each error and the IROC 
and TG-119 columns address the probability of the errors being detected after the fact 
with the current commissioning guidelines and credentialing procedures in place. The 
3D Dosimetry columns then assess the possible sensitivity of the current procedures if 
3D dosimetric indices were used rather than planar and point dose measurements. 
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5 Conclusion 
The AAA commissioning process within the Eclipse TPS is surprisingly robust to 
user error. The most severe of errors implemented was the input of TMR curve as 
opposed to PDD. While this error had severe clinical effects, it was easily detected with 
IROC credentialing and TG 119 commissioning. No commissioning errors were found to 
have both a low detection probability and high clinical severity. When errors do occur, 
the IROC credentialing and TG 119 commissioning criteria are generally effective at 
detecting them; however OAR TLDs are the most sensitive despite the IROC currently 
excluding them from analysis. IROC film analysis was ineffective in detecting the 
commissioning errors that we implemented. 3D dosimetry is more sensitive than the 
current 2D planar comparisons at detecting errors made in commissioning the dose 
calculation algorithm especially in the low dose region, but is roughly equivalently 
sensitive to the TLD point dose measurements currently done in IROC credentialing. It 
is also critically necessary to do absolute dose plane comparison rather than relative 
comparison, as relative gamma analysis was unable to detect even the most dramatic of 
commissioning errors. 
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